Sergej M. Kiprijanov
Plus aucun poste en cours
Profil
Dr. Sergej M.
Kiprijanov is a Director-Preclinical & Biologics at BerGenBio AS.
Dr. Kiprijanov was previously employed as a Principal by Novoplant GmbH, Head-Research & Development by Affimed Therapeutics AG, a Principal by German Cancer Research Center, and VP-Discovery, Research & Preclinical Development by Affitech A.
He received his undergraduate degree from Novosibirsk State University and a doctorate degree from the Moscow Institute of Physics & Technology.
Anciens postes connus de Sergej M. Kiprijanov
| Sociétés | Poste | Fin |
|---|---|---|
Affimed NV Niederlassung Deutschland
 Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Directeur Technique/Scientifique/R&D | 01/01/2006 |
German Cancer Research Center
 German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany. | Corporate Officer/Principal | - |
| BERGENBIO ASA | Corporate Officer/Principal | - |
Affitech A/S
 Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Corporate Officer/Principal | - |
Novoplant GmbH
 Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Directeur Technique/Scientifique/R&D | 05/11/2009 |
Formation de Sergej M. Kiprijanov
| Moscow Institute of Physics & Technology | Doctorate Degree |
| Novosibirsk State University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BERGENBIO ASA | Health Technology |
| Entreprise privées | 4 |
|---|---|
Affimed NV Niederlassung Deutschland
Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Health Technology |
Novoplant GmbH
Novoplant GmbH Agricultural Commodities/MillingProcess Industries Novoplant GmbH develops and provides veterinary medicines. It produces antibodies and antibody fragments in plants for veterinary use to fight intestinal pathogens. It received a license for the development and commercialization of therapeutic antibodies as feed components for use in veterinary medicine. It will use MorphoSys’s HuCAL GOLD technology to generate antibodies against viruses, parasites and pathogenic microorganisms. The addition of such antibodies to animal feed stock may offer protection against infectious diseases in the respective animal’s gastro-intestinal tract. The company was founded in 1998 and is headquartered in Gatersleben, Germany. | Process Industries |
German Cancer Research Center
German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany. | Health Services |
Affitech A/S
Affitech A/S Pharmaceuticals: MajorHealth Technology Affitech A/S engages in the development of human antibody therapeutics. It focuses on human antibodies for cancer such as hematological and solid tumors; and serious inflammatory conditions including rheumatoid arthritis and severe asthma. The firm enters into partnerships and collaborations with biotechnology companies for antibody discovery and development. The company was founded by Søren Mouritsen and Henrik Irgang Elsner on October 1, 1990 and is headquartered in Copenhagen, Denmark. | Health Technology |
